Sign In
Buy QURE
$29.88
+3.12 (+11.66%)
At Close: Jun 03, 2026
uniQure N.V.: A Potential Huntington's Play
01:47am, Wednesday, 26'th Feb 2025
uniQure's stock surged in December due to positive data around its Huntington's disease candidate AMT-130, clearing the way for potential accelerated FDA approval without another trial. The company's
uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons
03:07pm, Thursday, 20'th Feb 2025
uniQure's gene therapy AMT-130 for Huntington's Disease shows promising clinical data, with an 80% reduction in disease progression, positioning it for potential FDA approval. Despite past commercial
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
01:04pm, Friday, 07'th Feb 2025
CSL Limited CSLLY and uniQure Inc QURE announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of Hemgenix (etranacogene de
94 percent of patients eliminated factor IX prophylaxis and remained free of continuous prophylaxis through four years post-treatment Mean factor IX activity levels were sustained at near normal level
~ Independent Data Monitoring Committee recommends proceeding with dosing of second cohort after planned safety assessment ~
~ Independent Data Monitoring Committee Recommends Proceeding with Dose Escalation After Planned Safety Assessment of First Dose Cohort ~
uniQure Announces Pricing of its Public Offering
07:05am, Wednesday, 08'th Jan 2025
LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,
uniQure Announces Proposed Public Offering
04:49pm, Tuesday, 07'th Jan 2025
LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?
04:31am, Sunday, 15'th Dec 2024
Shares of the international gene therapy developer uniQure (QURE 2.26%) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the company's
QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug
11:06am, Wednesday, 11'th Dec 2024
uniQure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to treat Huntington's disease.
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease
07:05am, Tuesday, 10'th Dec 2024
~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License Applica
Wall Street Analysts Think uniQure (QURE) Could Surge 228.07%: Read This Before Placing a Bet
10:57am, Friday, 29'th Nov 2024
The consensus price target hints at a 228.1% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
What Makes uniQure (QURE) a New Buy Stock
01:05pm, Thursday, 28'th Nov 2024
uniQure (QURE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LEXINGTON, Mass. and AMSTERDAM, Nov. 21, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,
Wall Street Analysts Believe uniQure (QURE) Could Rally 169.18%: Here's is How to Trade
10:55am, Friday, 08'th Nov 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 169.2% in uniQure (QURE). While the effectiveness of this highly sought-after metric is questionable, the posit
